Hiperpigmentasi Pasca-inflamasi

01Pathophysiology

PIH develops because any inflammatory process in the skin can dysregulate melanocyte activity. The inflammatory cascade releases prostaglandins, leukotrienes, reactive oxygen species (ROS), and pro-inflammatory cytokines such as IL-1, TNF-alpha, and endothelin-1. These mediators stimulate melanocytes to upregulate tyrosinase activity, leading to increased melanin synthesis. The excess melanin is then transferred to surrounding keratinocytes via melanosomes, producing visible darkening of the skin at the site of prior inflammation.

This explains why the pigmentation maps perfectly to the distribution of the original lesion. A patient who had acne on the cheeks will develop hyperpigmented macules on the cheeks. A patient who had eczema on the antecubital fossae will show darkened patches in that same location. The pigmentation is not random; it is a direct consequence of localized melanocyte stimulation.

In more severe or deeper inflammation, damage to the basal layer of the epidermis causes melanin granules to "drop" into the upper dermis, a process known as melanin incontinence. Once in the dermis, this free melanin is engulfed by dermal macrophages (melanophages). Dermal PIH has a blue-gray hue and is far more persistent and difficult to treat than the epidermal form, because melanophages can retain melanin for prolonged periods. Understanding this epidermal-versus-dermal distinction is critical because it directly determines prognosis and treatment response.

The reason darker-skinned patients are more susceptible is straightforward: they have larger, more numerous, and more widely distributed melanosomes within their melanocytes. These melanocytes are more reactive to inflammatory stimuli, producing a disproportionate melanin response compared to lighter skin phototypes exposed to the same insult.

02Classification and Clinical Manifestation

Common precipitating conditions and their typical PIH patterns:

03Diagnostic Workup

PIH is fundamentally a clinical diagnosis. You do not need a biopsy in straightforward cases. The history of a preceding inflammatory dermatosis at the exact location of the current hyperpigmentation is the single most important diagnostic clue.

The Wood's lamp examination is the best initial test when you need to classify the depth of pigment involvement. This step matters for management planning because epidermal PIH is treatable with topical depigmenting agents, while dermal PIH has a limited response to these same therapies. A vignette may describe a patient with persistent dark patches and ask what to do next: the answer is Wood's lamp examination to determine depth, which will guide your treatment selection.

Biopsy is reserved for cases where the diagnosis is in doubt, particularly when you cannot confirm a preceding inflammatory condition, when the hyperpigmentation is progressive despite treatment, or when a melanocytic neoplasm needs to be excluded. Histopathology in epidermal PIH shows increased melanin content in basal keratinocytes and sometimes melanocyte hyperplasia. In dermal PIH, you will see melanophages (pigment-laden macrophages) in the papillary dermis, sometimes accompanied by a perivascular lymphocytic infiltrate.

04Management and Treatment

The first and non-negotiable step for every patient with PIH is strict sun protection. Ultraviolet radiation stimulates melanogenesis and will worsen existing PIH regardless of any treatment applied. Broad-spectrum sunscreen with SPF 30 or higher must be used daily, with reapplication every two hours during sun exposure. This is the "next best step" in any vignette where a patient with PIH is not already on photoprotection.

The second step is to treat the underlying inflammatory condition. If acne is still active, manage the acne. If eczema is flaring, treat the eczema. Failing to control the primary process will perpetuate the cycle of inflammation and melanin overproduction.

For depigmentation therapy, hydroquinone remains the most established topical agent. It works by inhibiting tyrosinase, the rate-limiting enzyme in melanin synthesis. The 2% concentration is available without a prescription, while 4% requires one. It is applied once to twice daily for a duration of 4 to 6 months. Continuous use beyond this timeframe risks exogenous ochronosis, a paradoxical blue-black discoloration of the skin that is disfiguring and difficult to reverse. This is a commonly tested complication.

Tretinoin (a topical retinoid) accelerates epidermal turnover, promoting the shedding of melanin-laden keratinocytes and improving penetration of other topical agents. It is applied nightly, starting at a lower concentration (0.025%) and titrating up as tolerated. Visible improvement takes 8 to 12 weeks. Tretinoin is contraindicated in pregnancy (Category X).

Azelaic acid at 15 to 20% is an important alternative because it is safe in pregnancy, unlike hydroquinone and tretinoin, which should be avoided. It also provides anti-inflammatory benefits, making it useful for PIH secondary to acne or rosacea.

Kligman's formula (the triple combination of hydroquinone, tretinoin, and a low-potency topical corticosteroid) is the most effective topical regimen studied for PIH. The corticosteroid component reduces inflammation and the irritation caused by the other two agents. Apply nightly for 8 to 12 weeks, then reassess.

For refractory cases, procedural options include superficial chemical peels and laser therapy. The Q-switched Nd:YAG laser at 1064 nm is considered the safest laser for darker skin phototypes because its longer wavelength bypasses epidermal melanin and targets dermal melanophages. However, any laser in darker skin carries a risk of paradoxical post-procedural hyperpigmentation, so this option is reserved for cases that do not respond to topical therapy.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on PIH questions is by confusing it with melasma. Both present as facial hyperpigmentation in darker-skinned individuals, but the distinguishing feature is the relationship to a prior inflammatory condition. PIH has a clear temporal and spatial link to a preceding dermatosis (the dark spots appeared exactly where the acne or eczema was). Melasma has no such preceding lesion and follows a symmetric, hormonally driven pattern. If the vignette mentions "dark spots where her acne used to be," that is PIH. If it says "symmetric dark patches on the cheeks worsening during pregnancy," that is melasma.

A second trap involves the Wood's lamp. Students may skip this step and jump directly to prescribing hydroquinone. However, the exam tests whether you understand that dermal PIH (no Wood's lamp enhancement) will not respond well to topical depigmenting agents. The correct "next step" in a patient with blue-gray discoloration and no Wood's lamp enhancement is to counsel the patient about the limited efficacy of topical therapy, emphasize strict sun protection, and consider referral for laser evaluation rather than prescribing months of ineffective hydroquinone.

Third, watch for the exogenous ochronosis trap. A vignette may describe a patient who has been using hydroquinone for over a year and now presents with paradoxical blue-black darkening of the treated area. The answer is to discontinue the hydroquinone. Prolonged use is the cause, not the cure.

Finally, remember that in a pregnant patient with PIH, tretinoin and hydroquinone are avoided. The correct first-line topical agent in this setting is azelaic acid, which is safe in pregnancy and still effective.

The core competency being tested across all PIH questions is your ability to recognize a temporal cause-and-effect relationship between a prior skin insult and subsequent pigmentary change, distinguish it from look-alike diagnoses, classify the depth of involvement, and select the appropriate treatment while avoiding contraindicated therapies in special populations.